Agilent Technologies (A)
(Delayed Data from NYSE)
$137.32 USD
+2.34 (1.73%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $137.32 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$137.32 USD
+2.34 (1.73%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $137.32 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Zacks News
Santa Clara, CA-based Agilent Technologies, Inc. was originally a spin-off from Hewlett-Packard. The company is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG). The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers’ representatives, telesales and electronic commerce.
Square's (SQ) Robust Portfolio is Likely to Aid Q2 Earnings
by Zacks Equity Research
Square's (SQ) expanding financial services portfolio is likely to benefit its GPV in the second quarter.
TripAdvisor (TRIP) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
TripAdvisor's (TRIP) second-quarter results are likely to be driven by strong performance of its non-hotel segment. However, weakness in its hotel segment remains a concern.
Cypress' (CY) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cypress' (CY) second-quarter earnings results are driven by improving demand for its products and solid operating results.
Will New Products, Expansion Aid GoDaddy (GDDY) Q2 Earnings?
by Zacks Equity Research
Increasing demand for GoDaddy's (GDDY) new products and international expansion might favor its Q2 results. However, rising competition is a concern.
Will Innovative Products Aid Fitbit's (FIT) Q2 Earnings?
by Zacks Equity Research
Fitbit's (FIT) focus on healthcare platforms might benefit its second-quarter results. However, intensifying competition in the wearables market remains a major concern.
Fortive (FTV) Beats on Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Robust product portfolio and benefits from acquisitions drives Fortive's (FTV) second-quarter results.
Square (SQ) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Square's (SQ) second-quarter 2018 results are likely to benefit from improving presence in bitcoin space and growing GPV. However, acquisition costs and issuance of notes remain headwinds.
Can Growing Partnerships Drive Baidu's (BIDU) Q2 Earnings?
by Zacks Equity Research
Strong product portfolio and growing partnerships will likely drive Baidu's (BIDU) second-quarter results.
MobileIron (MOBL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Strong product portfolio and growing partnerships will likely drive MobileIron's (MOBL) second-quarter results.
Will Amkor (AMKR) Q2 Earnings Gain From Strong Auto Demand?
by Zacks Equity Research
Healthy growth in the automotive business and acquisition-related benefits are going to drive Amkor's (AMKR) second-quarter results.
Fortive (FTV) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Fortive's (FTV) second-quarter results are likely to benefit from expanding product portfolio and positive contributions from its strategic buyouts.
Mettler-Toledo (MTD) Q2 Earnings: Disappointment in Store?
by Zacks Equity Research
Mettler-Toledo's (MTD) second-quarter results are likely to benefit from robust laboratory business. However, weak product inspection business remains a concern.
What's in Store for Amphenol (APH) This Earnings Season?
by Zacks Equity Research
Amphenol (APH) is expected to benefit from organic and inorganic growth across most of its end markets in second-quarter 2018 results.
What's in the Cards for Waters Corp (WAT) in Q2 Earnings?
by Zacks Equity Research
Waters Corp (WAT) is scheduled to report second-quarter results which are likely to be driven by its strong position in the pharmaceutical market and robust mass spectrometry portfolio.
Agilent Acquires ULTRA Scientific Assets, Expands Portfolio
by Zacks Equity Research
Agilent (A) recently completes the buyout of the business assets of ULTRA Scientific, thereby expanding its already vast product portfolio.
Agilent (A) to Acquire ProZyme, Expand Glycan Market Share
by Zacks Equity Research
Agilent (A) agrees to acquire glycan analysis company ProZyme for an undisclosed amount.
Agilent (A) Opens Logistics Center, Expands China Foothold
by Zacks Equity Research
Agilent (A) opens a new logistics center in Shanghai to ensure timely delivery of its services in the country.
Agilent Technologies (A) Down 4.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Agilent Technologies (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agilent (A) Down 2.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agilent's AATI Acquisition to Strengthen Portfolio, Footprint
by Zacks Equity Research
Agilent (A) is set to acquire AATI, a developer of automated nucleic acid analysis systems using capillary electrophoresis methods, for $250 million.
Agilent (A) Q1 Earnings & Revenues Beat, '18 View Positive
by Zacks Equity Research
Agilent (A) first-quarter fiscal 2018 results benefit from robust top-line growth and improving end-market demand.
Is a Surprise Coming for Agilent Technologies (A) This Earnings Season?
by Zacks Equity Research
Agilent Technologies (A) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Agilent (A) Down 3.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Agilent (A) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Itron Extends SMECO Contract, Offers Outsourced Solution
by Zacks Equity Research
Itron's (ITRI) contract extension with SMECO anticipated to drive bookings growth in the near term.
Itron (ITRI) Q3 Earnings & Revenues Lag on Shipment Delays
by Zacks Equity Research
Itron's (ITRI) top and bottom lines missed the Zacks Consensus Estimate in Q3 on shipment delays. The company updated its full-year 2017 guidance.